Our Partners











Safe, Secure Blood Supply

The CHS advocates for access to a secure supply of the safest and most efficacious therapies for the treatment of inherited bleeding disorders.

Submissions on the funding of extended half‐life factor concentrates

Eloctate™ and Alprolix™, extended half-life factor VIII and factor IX for the treatment of hemophilia A and B, were recently approved by Health Canada. The provinces and territories are currently reviewing whether or not to add them to the list of factor concentrates reimbursed through the blood system budget, and then distributed by Canadian Blood Services and Héma-Québec. The Canadian Hemophilia Society has submitted its recommendations.

Click here to read the CHS recommendations re Eloctate.

Click here to read the CHS recommendations re Alprolix.